AmerisourceBergen Corporation (ABC) Income Statement Analysis

See more : Spirits Time International, Inc. (SRSG) Income Statement Analysis – Financial Results

Complete financial analysis of AmerisourceBergen Corporation (ABC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AmerisourceBergen Corporation, a leading company in the Medical – Distribution industry within the Healthcare sector.

You may be interested

AmerisourceBergen Corporation (ABC)

Industry: Medical - Distribution

Sector: Healthcare

Website: https://www.amerisourcebergen.com

About AmerisourceBergen Corporation

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994
Revenue	262.17B	238.59B	213.99B	189.89B	179.59B	167.94B	153.14B	146.85B	135.96B	119.57B	87.96B	79.49B	80.22B	77.95B	71.76B	70.19B	66.07B	61.20B	54.58B	53.18B	49.66B	45.23B	16.19B	11.65B	9.81B	8.67B	7.82B	5.55B	4.67B	4.30B
Cost of Revenue	253.21B	230.29B	207.05B	184.70B	174.45B	163.33B	148.60B	142.58B	132.43B	116.59B	85.45B	76.82B	77.68B	75.60B	69.66B	68.14B	63.75B	58.97B	52.60B	51.00B	47.41B	43.21B	15.49B	11.12B	9.33B	8.25B	7.43B	5.25B	4.40B	4.06B
Gross Profit	8.96B	8.30B	6.94B	5.19B	5.14B	4.61B	4.55B	4.27B	3.53B	2.98B	2.51B	2.67B	2.54B	2.36B	2.10B	2.05B	2.33B	2.23B	1.98B	2.18B	2.25B	2.02B	700.12M	520.89M	475.60M	423.10M	389.30M	304.90M	268.80M	243.30M
Gross Profit Ratio	3.42%	3.48%	3.24%	2.73%	2.86%	2.75%	2.97%	2.91%	2.60%	2.49%	2.85%	3.36%	3.17%	3.02%	2.93%	2.92%	3.52%	3.65%	3.63%	4.10%	4.53%	4.48%	4.32%	4.47%	4.85%	4.88%	4.98%	5.49%	5.76%	5.66%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-58.48M	888.84M	958.11M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	2.66B	2.46B	2.13B	2.09B	1.92B	1.59B	1.33B	1.23B	0.00	0.00	0.00	0.00	0.00	0.00	1.32B	324.14M	334.95M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	5.31B	4.85B	3.59B	2.77B	2.66B	2.46B	2.13B	2.09B	1.92B	1.59B	1.33B	1.23B	1.20B	1.16B	1.13B	1.12B	1.41B	1.40B	1.26B	1.21B	1.29B	1.22B	408.76M	303.04M	281.80M	254.90M	255.40M	195.40M	160.90M	150.70M
Other Expenses	1.31B	693.90M	505.17M	391.06M	462.41M	-25.47M	2.73M	5.05M	-13.60M	4.36M	-44.00K	5.83M	0.00	0.00	1.43B	1.43B	1.51B	1.48B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	6.62B	5.54B	4.10B	3.16B	3.13B	2.93B	2.53B	2.46B	2.16B	1.77B	1.50B	1.37B	1.33B	1.25B	1.20B	1.21B	1.50B	1.48B	1.34B	1.29B	1.36B	1.28B	427.63M	320.46M	301.70M	271.50M	269.70M	207.00M	171.00M	165.40M
Cost & Expenses	259.83B	235.83B	211.15B	187.86B	177.58B	166.25B	151.12B	145.03B	134.59B	118.36B	86.95B	78.19B	79.01B	76.85B	70.86B	69.35B	65.25B	60.45B	53.94B	52.29B	48.77B	44.49B	15.92B	11.44B	9.63B	8.52B	7.70B	5.45B	4.57B	4.22B
Interest Income	0.00	21.31M	8.47M	20.64M	37.71M	14.94M	3.86M	4.44M	2.99M	841.00K	1.15M	1.80M	2.18M	2.31M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	228.93M	210.67M	182.54M	137.88M	157.77M	174.70M	145.19M	139.91M	99.00M	76.86M	73.90M	95.42M	78.90M	72.49M	58.31M	32.24M	32.29M	12.46M	0.00	0.00	0.00	140.73M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	963.90M	1.11B	1.05B	391.06M	462.41M	465.13M	397.60M	364.74M	243.28M	185.29M	162.19M	141.05M	108.31M	86.46M	78.91M	95.88M	104.34M	96.93M	90.88M	87.09M	80.44M	66.58M	24.71M	17.42M	19.90M	16.60M	14.30M	11.60M	10.10M	14.70M
EBITDA	3.37B	3.47B	3.41B	2.43B	2.49B	2.08B	2.42B	2.19B	1.60B	1.40B	1.17B	1.45B	1.32B	1.19B	974.43M	950.52M	931.83M	841.25M	843.99M	994.88M	967.77M	833.49M	307.59M	216.73M	208.70M	194.90M	133.90M	109.50M	107.90M	272.40M
EBITDA Ratio	1.28%	1.46%	1.59%	1.28%	1.39%	1.24%	1.58%	1.49%	1.18%	1.17%	1.33%	1.82%	1.64%	1.53%	1.36%	1.35%	1.41%	1.37%	1.55%	1.87%	1.95%	1.84%	1.90%	1.86%	2.13%	2.25%	1.71%	1.97%	2.31%	6.33%
Operating Income	2.34B	2.37B	2.35B	2.04B	2.03B	1.44B	1.11B	1.53B	417.37M	778.88M	898.40M	1.25B	1.20B	1.10B	883.75M	827.86M	820.34M	748.71M	636.95M	890.43M	883.11M	718.43M	259.38M	200.43M	173.90M	151.60M	119.60M	97.90M	97.80M	77.90M
Operating Income Ratio	0.89%	0.99%	1.10%	1.07%	1.13%	0.86%	0.73%	1.04%	0.31%	0.65%	1.02%	1.58%	1.50%	1.42%	1.23%	1.18%	1.24%	1.22%	1.17%	1.67%	1.78%	1.59%	1.60%	1.72%	1.77%	1.75%	1.53%	1.76%	2.09%	1.81%
Total Other Income/Expenses	-179.90M	-183.32M	-132.34M	-7.33B	-1.06B	-266.26M	-92.46M	-134.86M	-143.22M	-105.46M	-73.94M	-89.60M	-72.10M	-75.87M	-59.68M	-66.52M	-35.29M	-8.08M	-168.12M	-130.06M	-156.98M	-146.38M	-56.54M	-40.73M	-54.60M	-68.80M	-41.60M	-35.90M	-52.30M	-242.50M
Income Before Tax	2.16B	2.18B	2.22B	-5.29B	967.11M	1.18B	967.89M	1.39B	274.15M	673.43M	824.46M	1.16B	1.13B	1.03B	824.07M	761.34M	785.05M	740.63M	468.83M	760.37M	726.13M	572.05M	202.83M	159.70M	119.30M	82.80M	78.00M	62.00M	45.50M	-164.60M
Income Before Tax Ratio	0.82%	0.91%	1.04%	-2.79%	0.54%	0.70%	0.63%	0.95%	0.20%	0.56%	0.94%	1.46%	1.41%	1.32%	1.15%	1.08%	1.19%	1.21%	0.86%	1.43%	1.46%	1.26%	1.25%	1.37%	1.22%	0.96%	1.00%	1.12%	0.97%	-3.83%
Income Tax Expense	428.26M	516.52M	677.25M	-1.89B	112.97M	-438.47M	553.40M	-37.02M	409.04M	389.40M	331.02M	454.95M	424.02M	391.02M	312.22M	292.27M	291.28M	272.62M	176.90M	291.98M	284.90M	227.11M	77.73M	60.69M	48.40M	32.30M	30.60M	19.30M	17.30M	7.80M
Net Income	1.75B	1.70B	1.54B	-3.40B	855.37M	1.66B	414.48M	1.43B	-134.89M	276.48M	433.71M	718.99M	706.62M	636.75M	503.40M	250.56M	469.17M	467.71M	319.20M	468.39M	441.23M	344.94M	125.10M	99.01M	67.50M	50.50M	45.40M	35.50M	10.20M	-207.70M
Net Income Ratio	0.67%	0.71%	0.72%	-1.79%	0.48%	0.99%	0.27%	0.97%	-0.10%	0.23%	0.49%	0.90%	0.88%	0.82%	0.70%	0.36%	0.71%	0.76%	0.58%	0.88%	0.89%	0.76%	0.77%	0.85%	0.69%	0.58%	0.58%	0.64%	0.22%	-4.83%
EPS	8.53	8.15	7.48	-16.60	4.07	7.53	1.90	6.73	-0.62	1.22	1.88	2.84	2.59	2.26	1.67	0.78	1.27	1.14	0.75	1.05	1.01	0.82	0.55	0.48	0.33	0.26	0.23	0.20	0.07	-5.19
EPS Diluted	8.53	8.04	7.39	-16.60	4.04	7.53	1.87	6.32	-0.62	1.17	1.84	2.80	2.54	2.22	1.66	0.77	1.25	1.13	0.74	0.99	0.95	0.77	0.50	0.48	0.33	0.25	0.23	0.19	0.07	-5.19
Weighted Avg Shares Out	204.59M	208.47M	205.92M	204.78M	210.17M	217.87M	218.38M	212.21M	217.79M	227.37M	231.07M	252.91M	272.47M	282.26M	300.57M	321.28M	370.36M	410.02M	425.26M	447.35M	435.38M	419.74M	228.74M	206.21M	202.79M	190.71M	198.35M	182.05M	145.71M	40.00M
Weighted Avg Shares Out (Dil)	204.59M	211.21M	208.47M	204.78M	211.84M	220.34M	221.60M	225.96M	217.79M	235.41M	235.35M	256.90M	277.72M	287.25M	302.75M	324.92M	375.77M	414.89M	431.08M	471.12M	463.82M	448.91M	251.23M	208.08M	206.73M	202.85M	200.42M	184.42M	145.71M	40.00M

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

May 29, 2023zacks.com

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Walgreens Sells AmerisourceBergen Shares To Raise $694 Million To Pay Down Debt

May 12, 2023forbes.com

Walgreens Boots Alliance has sold shares of AmerisourceBergen for proceeds of $694 million, which will be used "primarily for debt paydown and general corporate purposes."

AmerisourceBergen Announces Common Share Repurchase From Walgreens Boots Alliance

May 11, 2023businesswire.com

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's entry into...

Walgreens Boots Alliance Sells Shares of AmerisourceBergen Corporation for $694 Million of Initial Proceeds

May 11, 2023businesswire.com

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance sells shares of AmerisourceBergen Corporation for $694 million of initial proceeds.

St. Jude Children’s Research Hospital and iHeartCountry Celebrate 10-Year partnership

May 8, 2023businesswire.com

NEW YORK--(BUSINESS WIRE)--St. Jude Children's Research Hospital® and iHeartCountry will celebrate their 10-year partnership at the 2023 iHeartCountry Festival on Saturday, May 13 in Austin, TX. The partnership is part of iHeartMedia’s strong commitment to the St. Jude mission: Finding...

Should Value Investors Buy AmerisourceBergen (ABC) Stock?

May 5, 2023zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...

3 Reasons Growth Investors Will Love AmerisourceBergen (ABC)

May 4, 2023zacks.com

AmerisourceBergen (ABC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AmerisourceBergen Announces Pharmacy Telehealth Partnership with SteadyMD

May 4, 2023businesswire.com

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen (AB), a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare. The two organizations have kicked off their collaboration...

Is AmerisourceBergen (ABC) Outperforming Other Medical Stocks This Year?

May 3, 2023zacks.com

Here is how AmerisourceBergen (ABC) and Align Technology (ALGN) have performed compared to their sector so far this year.

AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View

May 2, 2023zacks.com

AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

AmerisourceBergen Corporation (ABC) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories